StockData
Calidi Biotherapeutics, Inc. logo

Calidi Biotherapeutics, Inc. (CLDI) stock

CLDINYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CLDWW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 3/30
$0.56−0.04 (-7.07%)

Close on Nov 17, 2026Market cap $1.45MP/E –Yield –

Earnings

Calidi Biotherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 26, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$1.47
-$2.21 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Calidi Biotherapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 26, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 13, 2026after the close––-$1.47Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026during market hours––-$2.94Release
Q1 FY2026ended Mar 31, 2026May 14, 2026during market hours––-$0.43Release
Q4 FY2025ended Dec 31, 2025Mar 27, 2026during market hours––$0.57Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025during market hours––-$2.21Release
Q2 FY2025ended Jun 30, 2025Aug 8, 2025during market hours––-$1.99Release
Q1 FY2025ended Mar 31, 2025May 14, 2025during market hours––-$0.18Release
Q4 FY2024ended Dec 31, 2024Mar 31, 2025during market hours––-$0.27Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024during market hours––-$0.65Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024during market hours––-$1.40Release
Q1 FY2024ended Mar 31, 2024May 15, 2024after the close––-$0.20Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Calidi Biotherapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Calidi Biotherapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Calidi Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. News
  4. Results
  5. Update
  6. Results
  7. Results
  8. News
  9. News
  10. News
  11. Update
  12. Results
  13. Results
  14. Update
  15. Update

See a number that looks wrong?